Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration

Equivalent potency to risankizumab with similar binding affinity and epitope demonstrated in several preclinical assays

Read more at globenewswire.com